Technology
Health
Pharmaceutical

Jazz Pharmaceuticals

$136.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.46 (1.84%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell JAZZ and other stocks, options, ETFs, and crypto commission-free!

About

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. Read More The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Dublin, Ireland.

Employees
1,360
Headquarters
Dublin, Dublin
Founded
2003
Market Cap
7.68B
Price-Earnings Ratio
18.62
Dividend Yield
0.00
Average Volume
594.69K
High Today
$137.18
Low Today
$134.03
Open Price
$136.38
Volume
363.60K
52 Week High
$184.00
52 Week Low
$113.52

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Europe (Non-UK)
Europe

News

Simply Wall St18h

Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) 16% ROE Better Than Average?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important.

34
Seeking Alpha21h

FDA approves Jazz Pharma's Sunosi

The FDA has approved Jazz Pharmaceuticals' (NASDAQ:JAZZ) Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved. It is expected to be available in the U.S. following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically within 90 days of FDA approval....

39
Markets InsiderMar 21

Jazz Pharma Gets FDA Nod For Sleep Disorder Drug Sunosi

(RTTNews) - The FDA has approved Jazz Pharmaceuticals plc's (JAZZ) once-daily Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

18

Earnings

$2.56
$2.92
$3.28
$3.64
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.